Tech Company Financing Transactions

G1 Therapeutics Funding Round

G1 Therapeutics, based in Research Triangle Park, secured $47 million from Cormorant Asset Management, AJU IB Investment and Cowen Capital Partners.

Transaction Overview

Company Name
G1 Therapeutics
Announced On
5/11/2016
Transaction Type
Venture Equity
Venture Equity
Amount
$46,999,999
Round
Series C
Investors

Cormorant Asset Management (Lead Investor) (Bihua Chen)

AJU IB Investment

Cowen Capital Partners

Eshelman Ventures (Fred Eshelman)

Franklin Templeton

Hatteras Venture Partners (Christy Shaffer)

Lumira Capital

MedImmune Ventures (Ronald Laufer)

Mountain Group Capital

RA Capital (Peter Kolchinsky)

Rock Springs Capital

Tavistock Life Sciences

Proceeds Purpose
G1 plans to use the proceeds to advance the clinical development of its lead CDK4/6 inhibitors, G1T28 and G1T38, and to expand its pipeline in multiple oncology indications. G1T28 is a potential first-in-class combination therapy that is currently in two proof-of-concept trials in patients with small-cell lung cancer. G1T38 is a potential best-in-class oral drug that will begin clinical development later this month.

Company Information

Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
700 Park Offices Dr. 200
Research Triangle Park, NC 27709
USA
Phone
919-213-9835
Website
www.g1therapeutics.com
Email Address
[email protected]
Overview
G1 Therapeutics (Nasdaq: GTHX) is a clinical-stage company developing small-molecule therapies to address significant unmet needs in oncology. The company is leveraging its proprietary kinase drug discovery platform to advance a pipeline of first-in-class compounds and best-in-class drug candidates.
Profile
G1 Therapeutics LinkedIn Company Profile
Social Media
G1 Therapeutics Company Twitter Account
Company News
G1 Therapeutics News
Facebook
G1 Therapeutics on Facebook
YouTube
G1 Therapeutics on YouTube

Management Team

Title
Name
Email & Social
Chief Executive Officer
Mark Velleca
  Mark Velleca LinkedIn Profile  Mark Velleca Twitter Account  Mark Velleca News  Mark Velleca on Facebook
Chief Medical Officer
Raj Malik
  Raj Malik LinkedIn Profile  Raj Malik Twitter Account  Raj Malik News  Raj Malik on Facebook
Chief Scientific Officer
Jay Strum
  Jay Strum LinkedIn Profile  Jay Strum Twitter Account  Jay Strum News  Jay Strum on Facebook
VP - Bus. Development
Mark Avagliano
  Mark Avagliano LinkedIn Profile  Mark Avagliano Twitter Account  Mark Avagliano News  Mark Avagliano on Facebook
VP - Bus. Development
John Demaree
  John Demaree LinkedIn Profile  John Demaree Twitter Account  John Demaree News  John Demaree on Facebook
VP - Operations
Terry Murdock
  Terry Murdock LinkedIn Profile  Terry Murdock Twitter Account  Terry Murdock News  Terry Murdock on Facebook

 

 

Browse more venture capital transactions:

Prev: 5/11/2016: Nearpod venture capital transaction
Next: 5/11/2016: Fluent venture capital transaction

 

Share this article

 

News on VC Transactions

We do our best to report on tech company VC transactions. All VC database entries on this site are sourced from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.

 

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary

 

Copyright © 2001-2024. Gaebler Ventures. All rights reserved.